Breaking News, Collaborations & Alliances

ANI in ANDA Pact with Sofgen

Will develop, market and distribute CV drug in U.S.

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ANI Pharmaceuticals has signed a binding letter of intent for the development of an oral soft gel prescription product with Sofgen Pharmaceuticals. The product, indicated for cardiovascular health, will be the subject of an ANDA filing. Sofgen will be responsible for the development, manufacturing and regulatory submission of the product and ANI will be responsible for marketing and distribution in the U.S. Arthur S. Przybyl, ANI’s president and chief executive officer, stated, “I a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters